Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: A genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb

Leukemia

Volumn 12, Issue 8, 1998, Pages 1266-1271

  Gronbaek K ^a,b   Nedergaard, T ^b   Andersen, M K ^c   Thor Straten, P ^b   Guldberg, P ^b   Moller P ^a   Zeuthen, J ^b   Ebbe Hansen, N ^a   Hou Jensen, K ^c   Ralfkiaer, E ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

Cell cycle genes; Cyclin D1; Mantle cell lymphoma; p15; p16; p53; pRb

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; DNA; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; CELL CYCLE; CLINICAL ARTICLE; DNA METHYLATION; FEMALE; GENE DELETION; GENE DISRUPTION; GENOTYPE; HUMAN; HUMAN TISSUE; MALE; MANTLE CELL LYMPHOMA; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 17344367982     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401090     Document Type: Article

References (28)

1. Weisenburger DD, Armitage JO. Mantle cell lymphoma - an entity comes of age. Blood 1996; 87: 4483-4494.
2. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf Peeters C, Falini B, Gatter KC et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
3. Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinocpathologic study of 80 cases. Blood 1997; 89: 2067-2078.
4. Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 1994; 91: 709-713.
5. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, Weinberg RA. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 1993; 73: 499-511.
6. Lukas J, Aagaard L, Strauss M, Bartek J. Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res 1995; 55: 4818-4823.
7. Jadayel DM, Lukas J, Nacheva E, Bartkova J, Stranks G, De Schouwer PJ, Lens D, Bartek J, Dyer MJ, Kruger AR, Catovsky D. Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519). Leukemia 1997; 11: 64-72.
8. Ralfkiaer E. Immunohistological markers for the diagnosis of cutaneous lymphomas. Semin Diagn Pathol 1991; 8: 62-72.
9. Pinyol M, Campo E, Nadal A, Terol MJ, Jares P, Nayach I, Fernandez PL, Piris MA, Montserrat E, Cardesa A. Detection of the bcl-1 rearrangement at the major translocation cluster in frozen and paraffin-embedded tissues of mantle cell lymphomas by polymerase chain reaction. Am J Clin Pathol 1996; 105: 532-537.
10. Horsman DE, Gascoyne RD, Coupland RW, Coldman AJ, Adomat SA. Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t(14;18) in follicular lymphoma. Am J Clin Pathol 1995; 103: 472-478.
11. Klefstrom J, Franssila K, Peltomaki P, Kaartinen M, Solin ML, Knuutila S. Major and minor breakpoint sites of chromosomal translocation t(14;18) in subtypes of non-Hodgkin's lymphomas. Leukemia Res 1994; 18: 245-250.
12. Crescenzi M, Seto M, Herzig CP, Weiss PD, Griffith RC, Korsmeyer SJ. Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease. Proc Natl Acad Sci USA 1988; 85: 4869-4873.
13. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996; 56: 150-153.
14. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC. Germline p16 mutations in familial melanoma. Nat Genet 1994; 8: 15-21.
15. Zeschnigk M, Lich C, Buiting K, Doerfler W, Horsthemke B. A single-tube PCR test for the diagnosis of Angelman and Prader - Willi syndrome based on allelic methylation differences at the SNRPN locus. Eur J Hum Genet 1997; 5: 94-98.
16. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-9826.
17. Guldberg P, Kirkin AF, Grønbæk K, thor Straten P, Ahrenkiel V, Zeuthen J. Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: a novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma. Int J Cancer 1997; 72: 780-783.
18. Guldberg P, Nedergaard T, Nielsen HJ, Olsen AC, Ahrenkiel V, Zeuthen J. Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer. Hum Mutat 1997; 9: 348-355.
19. Williams ME, Swerdlow SH, Rosenberg CL, Arnold A. Characterization of chromosome 11 translocation breakpoints at the bcl-1 and PRAD1 loci in centrocytic lymphoma. Cancer Res 1992; 52: 5541-5544.
20. Jares P, Campo E, Pinyol M, Bosch F, Miquel R, Fernandez PL, Sanchez Beato M, Soler F, Perez Losada A, Nayach I, Mallofre C, Piris MA, Montserrat E, Cardesa A. Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. Am J Pathol 1996; 148: 1591-1600.
21. Martinez JC, Piris MA, Sanchez Beato M, Villuendas R, Orradre JL, Algara P, Sanchez Verde L, Martinez P. Retinoblastoma (Rb) gene product expression in lymphomas. Correlation with Ki67 growth fraction. J Pathol 1993; 169: 405-412.
22. Ginsberg AM, Raffeld M, Cossman J. Inactivation of the retinoblastoma gene in human lymphoid neoplasms. Blood 1991; 77: 833-840.
23. Zukerberg LR, Benedict WF, Arnold A, Dyson N, Harlow E, Harris NL. Expression of the retinoblastoma protein in low-grade B-cell lymphoma: relationship to cyclin D1. Blood 1996; 88: 268-276.
24. Dreyling MH, Bullinger L, Ott G, Stilgenbauer S, Muller Hermelink HK, Bentz M, Hiddeman W, Dohner H. Alterations of the cyclinD1/p16-pRB pathway in mantle cell lymphoma. Cancer Res 1997; 57: 4608-4614.
25. Meehan R, Lewis J, Cross S, Nan X, Jeppesen P, Bird A. Transcriptional repression by methylation of CpG. J Cell Sci Suppl 1992; 16: 9-14.
26. Issa JP, Baylin SB, Herman JG. DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia 1997; 11 (Suppl. 1): 7-11.
27. Martinez Delgado B, Fernandez Piqueras J, Garcia MJ, Arranz E, Gallego J, Rivas C, Robledo M, Benitez J. Hypermethylation of a 5′ CpG island of p16 is a frequent event in non-Hodgkin's lymphoma. Leukemia 1997; 11: 425-428.
28. Ory K, Legros Y, Augun C, Soussi T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 1994; 13: 3496-3504.